We served as part of a transaction advisory team that successfully completed a three-part merger and acquisition and asset swap valued at over US$ 20 billion. The transaction is among the largest ever in the global pharmaceutical sector.
−In-depth analysis of mergers and acquisitions in the global pharmaceutical industry
−Data-driven insights into the implications of M&A on cost of medicines, procurement strategies and Africa’s health agenda.
−Paper based on consolidation of data from E&K Consulting’s own work and data from pharmaceutical companies, GAVI, Global Fund and Malaria No More.
−Sponsored by E&K Consulting